{"DataElement":{"publicId":"2730258","version":"1","preferredName":"Prior Disease or Disorder Diagnosis Type","preferredDefinition":"A description of the prior disease diagnosis.","longName":"2768787v1.0:2789687v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2768787","version":"1","preferredName":"Prior Disease or Disorder Diagnosis","preferredDefinition":"Earlier in time or order._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","longName":"PRIOR_DZ_DX","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2206712","version":"1","preferredName":"Prior Diseases and Disorders","preferredDefinition":"Earlier in time or order.:A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C25629:C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-0141-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2239981","version":"1","preferredName":"Diagnosis","preferredDefinition":"The process of identifying a disease by the signs and symptoms.","longName":"C15220","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FD4EEB-1C71-0B27-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-26","modifiedBy":"ONEDATA","dateModified":"2005-06-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"53180894-7626-5D73-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-07-28","endDate":null,"createdBy":"LEATHERJ","dateCreated":"2008-07-28","modifiedBy":"NYCHM","dateModified":"2017-01-31","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2789687","version":"1","preferredName":"Disease or Disorder Type","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Type; a subdivision of a particular kind of thing.","longName":"2789687v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Hodgkin lymphoma","valueDescription":"Hodgkin's Lymphoma","ValueMeaning":{"publicId":"2581278","version":"1","preferredName":"Hodgkin's Lymphoma","longName":"2581278","preferredDefinition":"A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells.  There are two distinct subtypes: nodular lymphocyte predominant Hodgkin's lymphoma and classical Hodgkin's lymphoma.  Hodgkin's lymphoma has a bimodal age distribution, and involves primarily lymph nodes.  Current therapy for Hodgkin's lymphoma has resulted in an excellent outcome and cure for the majority of patients. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hodgkin Lymphoma","conceptCode":"C9357","definition":"A lymphoma characterized by the presence of relatively few malignant cells called Reed-Sternberg cells and mononuclear Hodgkin cells that are admixed with nonneoplastic inflammatory cells. The malignant cells have a distinctive immunophenotype; they are positive for CD30 and CD15 and negative for CD3, CD20, and CD45.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A8B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-04-26","modifiedBy":"LEATHERJ","dateModified":"2008-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"580AFD31-AE97-5D1F-E044-0003BA3F9857","beginDate":"2008-09-29","endDate":null,"createdBy":"LEATHERJ","dateCreated":"2008-09-29","modifiedBy":"LEATHERJ","dateModified":"2008-09-29","deletedIndicator":"No"},{"value":"Non-Hodgkin lymphoma","valueDescription":"Non-Hodgkin's Lymphoma","ValueMeaning":{"publicId":"2789688","version":"1","preferredName":"Non-Hodgkin's Lymphoma","longName":"2789688","preferredDefinition":"Distinct from Hodgkin's lymphoma both morphologically and biologically, NHL lymphoma is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss.  The clinical course varies according to the morphologic type.  NHL is clinically classified as indolent, aggressive, or having a variable clinical course.  NHL can be of B-or T-/NK-cell lineage. --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Hodgkin Lymphoma","conceptCode":"C3211","definition":"Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"580AFD31-AE6F-5D1F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"LEATHERJ","dateCreated":"2008-09-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"C9725348-641D-2AFE-E040-BB89AD430EDA","beginDate":"2008-09-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-09-11","modifiedBy":"ONEDATA","dateModified":"2012-09-11","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2575365","version":"1","preferredName":"Unknown","longName":"2575365","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F372-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA0F5066-C194-5EDF-E040-BB89AD43740A","beginDate":"2012-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-09-19","modifiedBy":"ONEDATA","dateModified":"2012-09-19","deletedIndicator":"No"},{"value":"Breast cancer","valueDescription":"Breast Carcinoma","ValueMeaning":{"publicId":"3589907","version":"1","preferredName":"Breast Carcinoma","longName":"3589907","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9FF059F-8BC9-73AE-E040-BB89AD4367D2","latestVersionIndicator":"Yes","beginDate":"2012-09-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-09-18","modifiedBy":"ONEDATA","dateModified":"2012-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"C9FF059F-8BE1-73AE-E040-BB89AD4367D2","beginDate":"2008-09-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-09-18","modifiedBy":"ONEDATA","dateModified":"2012-09-18","deletedIndicator":"No"},{"value":"Amyloidosis","valueDescription":"Amyloidosis","ValueMeaning":{"publicId":"3210866","version":"1","preferredName":"Amyloidosis","longName":"3210866","preferredDefinition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amyloidosis","conceptCode":"C2868","definition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-ACBA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F260FE8E-C24B-B418-E040-BB89AD434FD7","beginDate":"2014-02-14","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-02-14","modifiedBy":"ONEDATA","dateModified":"2014-02-14","deletedIndicator":"No"},{"value":"Solitary plasmacytoma","valueDescription":"Solitary Plasmacytoma","ValueMeaning":{"publicId":"2951236","version":"1","preferredName":"Solitary Plasmacytoma","longName":"2951236","preferredDefinition":"A single focus of clonal (malignant) plasma cells either in the bone or in another anatomic site without peripheral blood involvement. --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Solitary Plasmacytoma","conceptCode":"C6932","definition":"A localized malignant neoplasm that arises in the bony skeleton or soft tissue. It is composed of clonal (malignant) plasma cells forming a tumor mass.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75819AE4-A79A-9D30-E040-BB89AD430B21","latestVersionIndicator":"Yes","beginDate":"2009-10-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-10-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F260FE8E-C25F-B418-E040-BB89AD434FD7","beginDate":"2014-02-14","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-02-14","modifiedBy":"ONEDATA","dateModified":"2014-02-14","deletedIndicator":"No"},{"value":"Plasma cell leukemia","valueDescription":"Plasma Cell Leukemia","ValueMeaning":{"publicId":"3210723","version":"1","preferredName":"Plasma Cell Leukemia","longName":"3210723","preferredDefinition":"An aggressive plasma cell neoplasm with usually short survival. It is characterized by the presence of neoplastic plasma cells in the peripheral blood. The peripheral blood plasma cells comprise more than 20% of the peripheral blood white cells. It may be the initial presentation of a plasma cell neoplasm or manifest as a terminal complication of plasma cell myeloma. Lymphadenopathy and organomegaly are frequent clinical signs, whereas bone pain and osteolytic lesions are less frequently present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasma Cell Leukemia","conceptCode":"C3180","definition":"An aggressive plasma cell neoplasm characterized by the presence of neoplastic plasma cells in the peripheral blood. It is characterized by the presence of a circulating clonal plasma cell count that exceeds 2x10^9/L or is 20% of the leukocyte differential count.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9482-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F260FE8E-C273-B418-E040-BB89AD434FD7","beginDate":"2014-02-14","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-02-14","modifiedBy":"ONEDATA","dateModified":"2014-02-14","deletedIndicator":"No"},{"value":"Smoldering myeloma","valueDescription":"Smoldering Myeloma","ValueMeaning":{"publicId":"3210729","version":"1","preferredName":"Smoldering Myeloma","longName":"3210729","preferredDefinition":"A plasma cell myeloma lacking clinical manifestations and organ impairment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Smoldering Multiple Myeloma","conceptCode":"C7149","definition":"Multiple myeloma lacking clinical manifestations and organ impairment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9574-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F260FE8E-C287-B418-E040-BB89AD434FD7","beginDate":"2014-02-14","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-02-14","modifiedBy":"ONEDATA","dateModified":"2014-02-14","deletedIndicator":"No"},{"value":"Multiple myeloma","valueDescription":"Plasma Cell Myeloma","ValueMeaning":{"publicId":"2559811","version":"1","preferredName":"Plasma Cell Myeloma","longName":"2559811","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B6B0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F260FE8E-C29B-B418-E040-BB89AD434FD7","beginDate":"2014-02-14","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-02-14","modifiedBy":"ONEDATA","dateModified":"2014-02-14","deletedIndicator":"No"},{"value":"Monoclonal gammopathy of unknown significance","valueDescription":"Monoclonal Gammopathy of Undetermined Significance","ValueMeaning":{"publicId":"2838621","version":"1","preferredName":"Monoclonal Gammopathy of Undetermined Significance","longName":"2838621","preferredDefinition":"A plasma cell disorder in which an abnormal amount of a single immunoglobulin is present in the serum. Up to 25% of cases of monoclonal gammopathy of undetermined significance (MGUS) progress to a B-cell malignancy or myeloma. MGUS may occur in conjunction with various carcinomas, chronic inflammatory and infectious conditions, and other diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Gammopathy of Undetermined Significance","conceptCode":"C3996","definition":"A condition in which an abnormal amount of a single immunoglobulin is present in the serum. This category includes IgM monoclonal gammopathy of undetermined significance and non-IgM monoclonal gammopathy of undetermined significance. Up to 25% of cases of monoclonal gammopathy of undetermined significance  progress to a B-cell malignancy or myeloma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-B0A2-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F260FE8E-C2D6-B418-E040-BB89AD434FD7","beginDate":"2014-02-14","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-02-14","modifiedBy":"ONEDATA","dateModified":"2014-02-14","deletedIndicator":"No"},{"value":"Light chain deposition disease","valueDescription":"Light Chain Deposition Disease","ValueMeaning":{"publicId":"3928712","version":"1","preferredName":"Light Chain Deposition Disease","longName":"3928712","preferredDefinition":"A condition in which plasma cells secrete immunoglobulin light chains of only one type, kappa or lambda. Light chain deposition disease is often associated with multiple myeloma or lymphoproliferative disease, but as many as 50% of patients have no evidence of neoplastic plasma cell proliferation. Light chains excreted in the urine are known as Bence Jones protein. Amyloidosis and severe renal failure occur more frequently than in multiple myeloma. Also known as Bence Jones myeloma. L-chain disease, L-chain myeloma, and LCDD. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Light Chain Deposition Disease","conceptCode":"C7727","definition":"A condition in which plasma cells secrete immunoglobulin light chains of only one type, kappa or lambda. Light chain deposition disease is often associated with multiple myeloma or lymphoproliferative disease, but as many as 50% of patients have no evidence of neoplastic plasma cell proliferation. Light chains excreted in the urine are known as Bence Jones protein. Amyloidosis and severe renal failure occur more frequently than in multiple myeloma. Also known as Bence Jones myeloma. L-chain disease, L-chain myeloma, and LCDD.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E97C7BE5-6B3B-5A74-E040-BB89AD431D30","latestVersionIndicator":"Yes","beginDate":"2013-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F260FE8E-C2E0-B418-E040-BB89AD434FD7","beginDate":"2014-02-14","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-02-14","modifiedBy":"ONEDATA","dateModified":"2014-02-14","deletedIndicator":"No"},{"value":"Osteosclerotic myeloma / POEMS syndrome","valueDescription":"Osteosclerotic Myeloma","ValueMeaning":{"publicId":"3928714","version":"1","preferredName":"Osteosclerotic Myeloma","longName":"3928714","preferredDefinition":"A plasma cell neoplasm associated with osteosclerotic and fibrotic changes in the bone trabeculae.  Often, the lymph nodes show changes resembling the plasma cell variant of Castleman disease.  It is often part of POEMS syndrome which is characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Osteosclerotic Multiple Myeloma","conceptCode":"C7765","definition":"Multiple myeloma associated with osteosclerotic and fibrotic changes in the bone trabeculae.  Often, the lymph nodes show changes resembling the plasma cell variant of Castleman disease.  It is often part of POEMS syndrome which is characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E97C7BE5-6B61-5A74-E040-BB89AD431D30","latestVersionIndicator":"Yes","beginDate":"2013-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F260FE8E-C2EA-B418-E040-BB89AD434FD7","beginDate":"2014-02-14","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-02-14","modifiedBy":"ONEDATA","dateModified":"2014-02-14","deletedIndicator":"No"},{"value":"Other disease","valueDescription":"Other Disease or Disorder","ValueMeaning":{"publicId":"3158622","version":"1","preferredName":"Other Disease or Disorder","longName":"3158622","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94B8AE1D-5BF8-C169-E040-BB89AD435EB4","latestVersionIndicator":"Yes","beginDate":"2010-11-10","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-11-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"083A07DD-C701-8C69-E050-BB89AD437CB1","beginDate":"2008-09-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-11-19","modifiedBy":"ONEDATA","dateModified":"2014-11-19","deletedIndicator":"No"},{"value":"MDS","valueDescription":"Myelodysplastic Syndrome","ValueMeaning":{"publicId":"3946618","version":"1","preferredName":"Myelodysplastic Syndrome","longName":"3946618","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA87B0E5-6712-6876-E040-BB89AD437204","latestVersionIndicator":"Yes","beginDate":"2013-11-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-06","modifiedBy":"GDEEN","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0A5D3A34-B216-ABB9-E050-BB89AD4326EF","beginDate":"2014-12-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-12-16","modifiedBy":"ONEDATA","dateModified":"2014-12-16","deletedIndicator":"No"},{"value":"Sickle cell disease","valueDescription":"Sickle Cell Disease","ValueMeaning":{"publicId":"3301976","version":"1","preferredName":"Sickle Cell Disease","longName":"3301976","preferredDefinition":"A blood disorder characterized by the appearance of sickle-shaped red blood cells and anemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sickle Cell Disease","conceptCode":"C34383","definition":"A blood disorder characterized by the appearance of sickle-shaped red blood cells and anemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B128A231-DFDE-22B8-E040-BB89AD436DCB","latestVersionIndicator":"Yes","beginDate":"2011-11-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-11-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2D01C5F2-99EA-EABD-E050-BB89AD431D48","beginDate":"2016-03-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-03-01","modifiedBy":"ONEDATA","dateModified":"2016-03-01","deletedIndicator":"No"},{"value":"Myelofibrosis","valueDescription":"Myelofibrosis","ValueMeaning":{"publicId":"4264965","version":"1","preferredName":"Myelofibrosis","longName":"4264965","preferredDefinition":"A partial or complete replacement of the bone marrow stroma by fibrous tissue.  It can be a primary bone marrow lesion as part of the chronic myeloproliferative disorders (chronic idiopathic myelofibrosis), a manifestation of acute myeloid leukemia (acute panmyelosis with myelofibrosis), or a secondary phenomenon due to bone marrow involvement by a metastatic tumor (e.g., metastatic breast carcinoma). --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelofibrosis","conceptCode":"C3248","definition":"A partial or complete replacement of the bone marrow stroma by fibrous tissue.  It can be a primary bone marrow lesion as part of the chronic myeloproliferative disorders (chronic idiopathic myelofibrosis), a manifestation of acute myeloid leukemia (acute panmyelosis with myelofibrosis), or a secondary phenomenon due to bone marrow involvement by a metastatic tumor (e.g., metastatic breast carcinoma). --2003","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3B91-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2D01C5F2-99F4-EABD-E050-BB89AD431D48","beginDate":"2016-03-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-03-01","modifiedBy":"ONEDATA","dateModified":"2016-03-01","deletedIndicator":"No"},{"value":"Grade I endometrial cancer","valueDescription":"Grade 1 Endometrial Carcinoma","ValueMeaning":{"publicId":"5722271","version":"1","preferredName":"Grade 1 Endometrial Carcinoma","longName":"5722271","preferredDefinition":"A morphologic qualifier indicating that a cancerous lesion is well differentiated.: A malignant tumor arising from the epithelium that lines the cavity of the uterine body.  The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases.  Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma.  Uterine bleeding is an initial clinical sign.  The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 1","conceptCode":"C28077","definition":"A morphologic qualifier indicating that a cancerous lesion is well differentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Endometrial Carcinoma","conceptCode":"C7558","definition":"A malignant tumor arising from the epithelium that lines the cavity of the uterine body.  The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases.  Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma.  Uterine bleeding is an initial clinical sign.  The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B435711-00D4-3741-E053-F662850A50A1","latestVersionIndicator":"Yes","beginDate":"2017-03-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-03-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4B435711-00ED-3741-E053-F662850A50A1","beginDate":"2017-03-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-03-21","modifiedBy":"ONEDATA","dateModified":"2017-03-21","deletedIndicator":"No"},{"value":"Endometrial intraepithelial neoplasia","valueDescription":"Endometrial Intraepithelial Neoplasia","ValueMeaning":{"publicId":"5722273","version":"1","preferredName":"Endometrial Intraepithelial Neoplasia","longName":"5722273","preferredDefinition":"A premalignant neoplastic process that affects the endometrial epithelium and glands. It is characterized by architectural glandular alterations and cytological abnormalities in the epithelial cells. The lesion exceeds 1 mm in maximum linear dimension.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia","conceptCode":"C27789","definition":"A neoplastic clonal expansion of endometrial glands characterized by cytologic changes of the epithelium and the presence of an increased number of endometrial glands. The glands form crowded aggregates with tubular or branching patterns which are cytologically distinct from the background architectural and cytological pattern. It is associated with molecular changes seen in endometrioid endometrial carcinoma, including microsatellite instability, PAX2 inactivation, and PTEN, KRAS, and CTNNB1 gene mutations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B435711-00FA-3741-E053-F662850A50A1","latestVersionIndicator":"Yes","beginDate":"2017-03-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-03-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4B435711-0113-3741-E053-F662850A50A1","beginDate":"2017-03-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-03-21","modifiedBy":"ONEDATA","dateModified":"2017-03-21","deletedIndicator":"No"},{"value":"Complex atypical hyperplasia","valueDescription":"Complex Endometrial Hyperplasia with Atypia","ValueMeaning":{"publicId":"3250152","version":"1","preferredName":"Complex Endometrial Hyperplasia with Atypia","longName":"3250152","preferredDefinition":"A hyperplasia characterized by excessive proliferation of endometrial cells, resulting in the formation of complex epithelial structures.  It is associated with cytologic atypia and an increased risk of endometrial adenocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complex Endometrial Hyperplasia with Atypia","conceptCode":"C35560","definition":"A hyperplasia characterized by excessive proliferation of endometrial cells, resulting in the formation of complex epithelial structures.  It is associated with cytologic atypia and an increased risk of endometrial adenocarcinoma.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6DE8128-E8E5-E018-E040-BB89AD437315","latestVersionIndicator":"Yes","beginDate":"2011-06-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4B435711-0127-3741-E053-F662850A50A1","beginDate":"2017-03-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-03-21","modifiedBy":"ONEDATA","dateModified":"2017-03-21","deletedIndicator":"No"},{"value":"Grade 2 endometrial cancer","valueDescription":"Grade 2 Endometrial Endometrioid Adenocarcinoma","ValueMeaning":{"publicId":"6676489","version":"1","preferredName":"Grade 2 Endometrial Endometrioid Adenocarcinoma","longName":"6676489","preferredDefinition":"A primary endometrioid adenocarcinoma of the endometrium that contains 6-50% non-squamous solid areas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma","conceptCode":"C40147","definition":"Endometrial endometrioid adenocarcinoma exhibiting 6-50% solid non-glandular, non-squamous growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8461D58C-D7DD-1C22-E053-F662850AF14B","latestVersionIndicator":"Yes","beginDate":"2019-03-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-03-18","modifiedBy":"ONEDATA","dateModified":"2019-03-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8461D58C-D7F6-1C22-E053-F662850AF14B","beginDate":"2019-03-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-03-18","modifiedBy":"ONEDATA","dateModified":"2019-03-18","deletedIndicator":"No"},{"value":"Monoclonal gammopathy of renal significance","valueDescription":"Monoclonal Gammopathy of Renal Significance","ValueMeaning":{"publicId":"6682421","version":"1","preferredName":"Monoclonal Gammopathy of Renal Significance","longName":"6682421","preferredDefinition":"A condition caused by a B-cell or plasma cell clone resulting in the deposition of the secreted monoclonal immunoglobulin, without evidence for overt lymphoma or myeloma. This category includes a wide spectrum of renal pathology and include such lesions as immunoglobulin-associated amyloidosis, the monoclonal immunoglobulin deposition diseases (MIDDs; light chain deposition disease, heavy chain deposition disease, and light and heavy chain deposition disease), proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID), C3 glomerulopathy with monoclonal gammopathy, light chain proximal tubulopathy (Fanconi syndrome), and several others.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Gammopathy of Renal Significance","conceptCode":"C157343","definition":"A condition caused by a B-cell or plasma cell clone resulting in the deposition of the secreted monoclonal immunoglobulin, without evidence for overt lymphoma or myeloma. This category includes a wide spectrum of renal pathology and include such lesions as immunoglobulin-associated amyloidosis, the monoclonal immunoglobulin deposition diseases (MIDDs; light chain deposition disease, heavy chain deposition disease, and light and heavy chain deposition disease), proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID), C3 glomerulopathy with monoclonal gammopathy, light chain proximal tubulopathy (Fanconi syndrome), and several others.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"857B3357-58C2-4A70-E053-F662850A39C6","latestVersionIndicator":"Yes","beginDate":"2019-04-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-04-01","modifiedBy":"ONEDATA","dateModified":"2019-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"857B3357-58DB-4A70-E053-F662850A39C6","beginDate":"2019-04-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-04-01","modifiedBy":"ONEDATA","dateModified":"2019-04-01","deletedIndicator":"No"},{"value":"Multiple myeloma - non-secretory","valueDescription":"Non-Secretory Myeloma","ValueMeaning":{"publicId":"2688913","version":"1","preferredName":"Non-Secretory Myeloma","longName":"2688913","preferredDefinition":"A rare type of multiple myeloma in which the plasma cells synthesize but do not secrete immunoglobulins.  As a result, none of the immunoglobulins appear out of the normal range.  The symptoms are generally the same with those of immunoglobulin-secreting myeloma; however, the incidence of renal insufficiency is lower in non-secretory myeloma.  The diagnosis can be missed because of the absence of monoclonal immunoglobulin in the serum or urine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Secretory Multiple Myeloma","conceptCode":"C4734","definition":"A rare type of multiple myeloma in which the plasma cells synthesize but do not secrete immunoglobulins.  As a result, none of the immunoglobulins appear out of the normal range.  The symptoms are generally the same with those of immunoglobulin-secreting myeloma; however, the incidence of renal insufficiency is lower in non-secretory myeloma.  The diagnosis can be missed because of the absence of monoclonal immunoglobulin in the serum or urine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4C44B0-2024-5F6E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"857B3357-58EF-4A70-E053-F662850A39C6","beginDate":"2019-04-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-04-01","modifiedBy":"ONEDATA","dateModified":"2019-04-01","deletedIndicator":"No"},{"value":"Multiple myeloma - light chain only","valueDescription":"Multiple Myeloma-Light Chain Only","ValueMeaning":{"publicId":"2688914","version":"1","preferredName":"Multiple Myeloma-Light Chain Only","longName":"2688914","preferredDefinition":"Only the light chain (kappa or lambda) of the immunoglobulin is defective.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Light Chain Multiple Myeloma","conceptCode":"C70605","definition":"A finding of multiple myeloma in which  the light chain (kappa or lambda) of the immunoglobulin is defective.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4C44B0-204B-5F6E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8579D062-FBA9-4A85-E053-F662850A5EC5","beginDate":"2019-04-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-04-01","modifiedBy":"ONEDATA","dateModified":"2019-04-01","deletedIndicator":"No"},{"value":"High-grade endometrial cancer","valueDescription":"Endometrial Serous Adenocarcinoma Endometrial Clear Cell Adenocarcinoma","ValueMeaning":{"publicId":"7264723","version":"1","preferredName":"Endometrial Serous Adenocarcinoma Endometrial Clear Cell Adenocarcinoma","longName":"7264723","preferredDefinition":"A high grade, aggressive adenocarcinoma arising from the endometrium.  It is characterized by the presence of complex papillary patterns with cellular budding.  Atypical mitoses, necrosis, and psammoma bodies may be present.  It is classified as type II endometrial carcinoma and it is not associated with endometrial hyperplasia.  It tends to invade deeply into the myometrium and spreads into the lymphatic vessels.  Patients frequently present with spread of the tumor beyond the uterus at the time of diagnosis.  The prognosis is usually poor.: A high-grade endometrial adenocarcinoma characterized by the presence of large neoplastic cells that display at least focal cytoplasmic clearing.  The neoplastic cells form papillary, glandular, or sheet-like structures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrial Serous Adenocarcinoma","conceptCode":"C27838","definition":"A high-grade, aggressive adenocarcinoma arising from the endometrium. It is characterized by the presence of complex papillary patterns with cellular budding. Atypical mitoses, necrosis, and psammoma bodies may be present. It is classified as type II endometrial carcinoma and it is not associated with endometrial hyperplasia. It tends to invade deeply into the myometrium and spreads into the lymphatic vessels. Patients frequently present with spread of the tumor beyond the uterus at the time of diagnosis. The prognosis is usually poor.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Endometrial Clear Cell Adenocarcinoma","conceptCode":"C8028","definition":"A high-grade endometrial adenocarcinoma characterized by the presence of large neoplastic cells that display at least focal cytoplasmic clearing.  The neoplastic cells form papillary, glandular, or sheet-like structures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4505CD3-8743-5E33-E053-F662850A8720","latestVersionIndicator":"Yes","beginDate":"2020-04-28","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-04-28","modifiedBy":"ONEDATA","dateModified":"2020-04-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A4505CD3-875C-5E33-E053-F662850A8720","beginDate":"2020-04-28","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-04-28","modifiedBy":"ONEDATA","dateModified":"2020-04-28","deletedIndicator":"No"},{"value":"No visible lesion","valueDescription":"No Lesion","ValueMeaning":{"publicId":"7415465","version":"1","preferredName":"No Lesion","longName":"7415465","preferredDefinition":"The non-affirmative response to a question.: A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lesion","conceptCode":"C3824","definition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF0D2B50-552B-37CF-E053-4EBD850AD922","latestVersionIndicator":"Yes","beginDate":"2020-09-11","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-09-11","modifiedBy":"ONEDATA","dateModified":"2020-09-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF0D2B50-5544-37CF-E053-4EBD850AD922","beginDate":"2020-09-11","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-09-11","modifiedBy":"ONEDATA","dateModified":"2020-09-11","deletedIndicator":"No"},{"value":"Plasmacytoma","valueDescription":null,"ValueMeaning":{"publicId":"3210724","version":"1","preferredName":"Plasmacytoma","longName":"3210724","preferredDefinition":"A malignant (clonal) proliferation of plasma cells that are cytologically and immunophenotypically identical to those of plasma cell myeloma, but manifest a localized osseous or extraosseous growth pattern. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasmacytoma","conceptCode":"C9349","definition":"A malignant neoplasm characterized by the presence of a monoclonal population of plasma cells forming a tumor mass.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-94B6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA3BA6D-991E-42AD-E063-731AD00A53DE","beginDate":"2024-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-23","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"Immuno-globulin-related (AL) amyloidosis","valueDescription":null,"ValueMeaning":{"publicId":"14679106","version":"1","preferredName":"AL Amyloidosis","longName":"14679106v1.00","preferredDefinition":"The most common type of amyloidosis. It is characterized by the monoclonal deposition of immunoglobulin light chain fragments in organs and tissues. It is associated with plasma cell or B-cell lymphoproliferative disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AL Amyloidosis","conceptCode":"C158963","definition":"The most common type of amyloidosis. It is characterized by the monoclonal deposition of immunoglobulin light chain fragments in organs and tissues. It is associated with plasma cell or B-cell lymphoproliferative disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F258220-69AA-5AC0-E063-731AD00A6909","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA3BA6D-991F-42AD-E063-731AD00A53DE","beginDate":"2024-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-23","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"POEMS syndrome","valueDescription":null,"ValueMeaning":{"publicId":"3211372","version":"1","preferredName":"POEMS Syndrome","longName":"3211372","preferredDefinition":"A syndrome characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes.  It is often associated with osteosclerotic myeloma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"POEMS Syndrome","conceptCode":"C80303","definition":"A syndrome characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes. It is associated with plasma cell dyscrasia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F497-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA3BA6D-9920-42AD-E063-731AD00A53DE","beginDate":"2024-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-23","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2789686","version":"1","preferredName":"Disease or Disorder Type","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Type; a subdivision of a particular kind of thing.","longName":"C2991:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"580AFD31-AE3B-5D1F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-29","endDate":null,"createdBy":"LEATHERJ","dateCreated":"2008-09-29","modifiedBy":"ONEDATA","dateModified":"2008-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"580AFD31-AE4C-5D1F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-29","endDate":null,"createdBy":"LEATHERJ","dateCreated":"2008-09-29","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","changeDescription":". Added 2 PVs for 2814r2. AK 3/1/16 Added 3 PVs for DCP.  AK 3/21/17 PV added for another team.  AK 3/18/19 Added 3 PVs for 2402. AK 4/1/19","administrativeNotes":"2024.1.23 PVs added per ticket request CADSR0003263. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"10115208","version":"1","longName":"QA Test CS","context":"TEST","ClassificationSchemeItems":[{"publicId":"10115209","version":"1","longName":"QA Test CSI","context":"TEST"}]},{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964927","version":"1","longName":"2010r1: Acute Myelogenous Leukemia Pre-HSCT Data","context":"NHLBI"}]},{"publicId":"3896529","version":"1","longName":"Consortia 2012 Studies","context":"DCP","ClassificationSchemeItems":[{"publicId":"5889185","version":"1","longName":"UWI2016-08-01","context":"DCP"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"PerformedDiagnosis:value","type":"HCT_BRIDG","context":"NHLBI"},{"name":"aml_base_prior_disease","type":"NMDP_FN","context":"NHLBI"},{"name":"AMLpre_assess_diag_prior_dis","type":"NMDP_FN","context":"NHLBI"},{"name":"mds_base_prior_disease","type":"NMDP_FN","context":"NHLBI"},{"name":"MDSpre_assess_diag_prior_dis","type":"NMDP_FN","context":"NHLBI"},{"name":"AMLP_DADX_prior_dis","type":"NMDP_FN","context":"NHLBI"},{"name":"DCP","type":"USED_BY","context":"DCP"}],"ReferenceDocuments":[{"name":"What was the prior disease di","type":"Preferred Question Text","description":"What was the prior disease diagnosis?","url":null,"context":"NHLBI"},{"name":"What was the recipient's prior disease?","type":"Alternate Question Text","description":"What was the recipient's prior disease?","url":null,"context":"NHLBI"},{"name":"Specify prior disease","type":"Alternate Question Text","description":"Specify prior disease","url":null,"context":"NHLBI"},{"name":"Specify prior disease","type":"Application Standard Question Text","description":"Specify prior disease","url":null,"context":"NHLBI"},{"name":"DCP Text- 1","type":"Alternate Question Text","description":"Diagnosis","url":null,"context":"DCP"},{"name":"DCP Text- 2","type":"Alternate Question Text","description":"Diagnosis Pathology","url":null,"context":"DCP"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4684F67D-BC6D-34EB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-02-19","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-02-19","modifiedBy":"CCURATOR","dateModified":"2022-04-30","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}